Plasma-derived Exosomal MiR-4732-5p is a Promising Noninvasive Diagnostic Biomarker for Epithelial Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2021 Apr 29

PMID 33910598

Citations 31

Authors

Jingjing Liu

Jigeun Yoo

Jung Yoon Ho

Yuyeon Jung

Sanha Lee

Soo Young Hur

Youn Jin Choi

Affiliations

Soon will be listed here.

Abstract

Background: Exosomal miRNAs regulate gene expression and play important roles in several diseases. We used exosomal miRNA profiling to investigate diagnostic biomarkers of epithelial ovarian cancer (EOC).

Methods: In total, 55 individuals were enrolled, comprising healthy (n = 21) and EOC subjects (n = 34). Small mRNA (smRNA) sequencing and real-time PCR (RT-PCR) were performed to identify potential biomarkers. Receiver operating characteristic (ROC) curves were conducted to determine biomarker sensitivity and specificity.

Results: Using smRNA sequencing, we identified seven up-regulated (miR-4732-5p, miR-877-5p, miR-574-3p, let-7a-5p, let-7b-5p, let-7c-5p, and let-7f-5p) and two down-regulated miRNAs (miR-1273f and miR-342-3p) in EOC patients when compared with healthy subjects. Of these, miR-4732-5p and miR-1273f were the most up-regulated and down-regulated respectively, therefore they were selected for RT-PCR analysis. Plasma derived exosomal miR-4732-5p had an area under the ROC curve of 0.889, with 85.7% sensitivity and 82.4% specificity in distinguishing EOC patients from healthy subjects (p<0.0001) and could be a potential biomarker for monitoring the EOC progression from early stage to late stage (p = 0.018).

Conclusions: Plasma derived exosomal miR-4732-5p may be a promising candidate biomarker for diagnosing EOC.

Citing Articles

Global research trends in liquid biopsy for ovarian cancer from 1999 to 2023: A 25-year bibliometric analysis.

Wan J, Rao Z, Liu H, Wan J J Liq Biopsy. 2025; 5:100158.

PMID: 40027939 PMC: 11863938. DOI: 10.1016/j.jlb.2024.100158.

Diagnostic and Prognostic Significance of Exosomes and Their Components in Patients With Cancers.

Moni Z, Hasan Z, Alam M, Roy N, Islam F Cancer Med. 2025; 14(1):e70569.

PMID: 39757782 PMC: 11702466. DOI: 10.1002/cam4.70569.

Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degeneration.

Tveit Solheim E, Vestrheim Thomsen L, Bjorge L, Anandan S, Peter E, Desestret V Ann Clin Transl Neurol. 2024; 11(12):3255-3266.

PMID: 39473143 PMC: 11651201. DOI: 10.1002/acn3.52232.

Exosomes in diagnostic and therapeutic applications of ovarian cancer.

Bhavsar D, Raguraman R, Kim D, Ren X, Munshi A, Moore K J Ovarian Res. 2024; 17(1):113.

PMID: 38796525 PMC: 11127348. DOI: 10.1186/s13048-024-01417-0.

Exosomal noncoding RNAs in gynecological cancers: implications for therapy resistance and biomarkers.

Xu C, Xu P, Zhang J, He S, Hua T, Huang A Front Oncol. 2024; 14:1349474.

PMID: 38737906 PMC: 11082286. DOI: 10.3389/fonc.2024.1349474.

References

Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T . Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(21):7677-82. PMC: 1140439. DOI: 10.1073/pnas.0502178102. View

Berchuck A, Havrilesky L, Kauff N . Is There a Role for Ovarian Cancer Screening in High-Risk Women?. J Clin Oncol. 2017; 35(13):1384-1386. DOI: 10.1200/JCO.2016.72.0045. View

Nelson P, Baldwin D, Marie Scearce L, Oberholtzer J, Tobias J, Mourelatos Z . Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods. 2005; 1(2):155-61. DOI: 10.1038/nmeth717. View

Kopkova A, Sana J, Machackova T, Vecera M, Radova L, Trachtova K . Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors. Cancers (Basel). 2019; 11(10). PMC: 6826583. DOI: 10.3390/cancers11101546. View

Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y . Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013; 8(11):e77853. PMC: 3815222. DOI: 10.1371/journal.pone.0077853. View

Wang Y, Zhao S, Yuan X, Liu Y, Zhang K, Wang J . miR-4732-5p promotes breast cancer progression by targeting TSPAN13. J Cell Mol Med. 2019; 23(4):2549-2557. PMC: 6433729. DOI: 10.1111/jcmm.14145. View

Fukumoto I, Kinoshita T, Hanazawa T, Kikkawa N, Chiyomaru T, Enokida H . Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. Br J Cancer. 2014; 111(2):386-94. PMC: 4102946. DOI: 10.1038/bjc.2014.293. View

Ying H, Lv J, Ying T, Li J, Yang Q . Screening of feature genes of the ovarian cancer epithelia with DNA microarray. J Ovarian Res. 2013; 6(1):39. PMC: 3683326. DOI: 10.1186/1757-2215-6-39. View

Aheget H, Mazini L, Martin F, Belqat B, Marchal J, Benabdellah K . Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases. Cancers (Basel). 2021; 13(1). PMC: 7795854. DOI: 10.3390/cancers13010084. View

10.

Shin H, Han C, Labuz J, Kim J, Kim J, Cho S . High-yield isolation of extracellular vesicles using aqueous two-phase system. Sci Rep. 2015; 5:13103. PMC: 4536486. DOI: 10.1038/srep13103. View

11.

Kozomara A, Griffiths-Jones S . miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013; 42(Database issue):D68-73. PMC: 3965103. DOI: 10.1093/nar/gkt1181. View

12.

Rupaimoole R, Calin G, Lopez-Berestein G, Sood A . miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016; 6(3):235-46. PMC: 4783232. DOI: 10.1158/2159-8290.CD-15-0893. View

13.

Nam E, Yoon H, Kim S, Kim H, Kim Y, Kim J . MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14(9):2690-5. DOI: 10.1158/1078-0432.CCR-07-1731. View

14.

Yoshida K, Yokoi A, Sugiyama M, Oda S, Kitami K, Tamauchi S . Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance. Oncogene. 2021; 40(7):1255-1268. PMC: 7892337. DOI: 10.1038/s41388-020-01595-3. View

15.

Choi D, Kim D, Kim Y, Gho Y . Proteomics of extracellular vesicles: Exosomes and ectosomes. Mass Spectrom Rev. 2014; 34(4):474-90. DOI: 10.1002/mas.21420. View

16.

Miles G, Seiler M, Rodriguez L, Rajagopal G, Bhanot G . Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012; 5:164. PMC: 3342161. DOI: 10.1186/1756-0500-5-164. View

17.

Kim H, Bae Y, Jeon J, Noh H, Park H, Byun D . The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. J Transl Med. 2019; 17(1):236. PMC: 6647278. DOI: 10.1186/s12967-019-1983-3. View

18.

Skokos D, Goubran Botros H, Demeure C, Morin J, Peronet R, Birkenmeier G . Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol. 2003; 170(6):3037-45. DOI: 10.4049/jimmunol.170.6.3037. View

19.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

20.

Pritchard C, Cheng H, Tewari M . MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012; 13(5):358-69. PMC: 4517822. DOI: 10.1038/nrg3198. View